Browsing Tag
Euronext Amsterdam
16 posts
OCI’s €4.10 cash offer gives shareholders an alternative to Orascom deal
OCI shareholders face a €4.10 cash offer from NNS while the Orascom Construction combination and remaining asset sales keep valuation in play.
Adyen (AMS: ADYEN) jumps 16% as growth guide rises but margins tighten
Adyen surged 16% after raising 2026 growth guidance. Can Talon.One, Orb and AI payments justify the €33bn valuation and higher spending?
WSP Global’s second Arcadis approach fails on price and paper currency concerns
Arcadis rejected WSP Global's €5.2 billion revised bid at €51.50 per share, citing undervaluation, WSP stock risk, and leverage inside a combined entity.
THEON posts 38% revenue growth as European military spending strengthens
THEON revenue rose 38% as a €1.46 billion backlog and drone acquisitions supported its push toward €1 billion in annual sales.
WSP Global raises Arcadis takeover offer to €51.50 as engineering consolidation accelerates
WSP Global raised its Arcadis takeover offer to €51.50 a share. See how the €4.4 billion bid could reshape global engineering.
Arcadis rejects WSP Global’s first bid, weighs revised €51.5 offer worth €4.4bn
WSP Global's revised €51.5 bid values Arcadis near €4.4bn, but the board rejected the earlier offer with Q2 results due 30 July setting the next test.
MotorK shifts Italy and Spain marketing delivery to Underdogs while keeping AdSparK
MotorK is transferring the labour-intensive side of digital marketing delivery while retaining the software platform, but investors still need evidence that the structure can protect revenue and improve margins.
ASML (NASDAQ: ASML) beats Q2 as €43-45bn 2026 sales guidance is raised
ASML (NASDAQ: ASML) beats Q2 at €9.3bn, raises 2026 sales outlook to €43-45bn and plans 30% capacity expansion for 2027 at both EUV and DUV lines.
Why Joenja’s pediatric expansion could strengthen Pharming Group’s long-term commercial runway
Find out how Pharming’s Joenja FDA review could affect PHAR stock sentiment, pediatric APDS access, and rare-disease revenue growth.
LTIMindtree’s LTM rebrand gets acquisition test with proposed Randstad technology services deal
LTM is buying Randstad’s tech services scale as AI demand shifts local. The real test is whether €469m revenue can become margin-rich growth.